As part of a multisite, international clinical trial, Mayo Clinic is the first organization in the U.S. to treat a patient with a new radiopharmaceutical drug to target metastatic breast cancer. The clinical trial investigates actinium-225 DOTATATE, a highly potent alpha-emitting radiopharmaceutical therapy, for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
“This treatment is the first of its kind for metastatic breast cancer, and it targets the most common subset,” says Rohit R. Rao, M.B.B.S., M.D., a medical oncologist at Mayo Clinic in Florida and co-investigator of the clinical trial. “Our hope is that radiopharmaceutical therapy will offer a benefit to our patients when other treatments haven’t been helpful.”
The phase 1b/2 open-label trial is underway at the Mayo Clinic academic sites in Minnesota, Arizona, and Florida and will roll out at approximately 20 other sites across the U.S. The first patient was treated with actinium-225 DOTATATE at Mayo Clinic in Florida.
